Cargando…

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report

In advanced lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutation, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have an excellent and long-lasting therapeutic response; however, virtually all patients eventually develop drug resistance and expe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shubin, Yu, Qitao, Jiang, Wei, Lu, Yukun, Zhao, Yun, Wang, Huilin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339383/ https://www.ncbi.nlm.nih.gov/pubmed/37457583 http://dx.doi.org/10.3389/fmed.2023.1168220

Ejemplares similares

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report
por: Lee, Sanghun, et al.
Publicado: (2018)

Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients
por: Matsuo, Norikazu, et al.
Publicado: (2016)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
por: Yu, Jiang-Yong, et al.
Publicado: (2016)

Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC
por: Jiang, Wei, et al.
Publicado: (2020)

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
por: Yamada, Yutaka, et al.
Publicado: (2021)

The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
por: Zhang, Yaxiong, et al.
Publicado: (2017)

MicroRNA Signature of Lung Adenocarcinoma with EGFR Exon 19 Deletion
por: Ju, Lixia, et al.
Publicado: (2017)

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
por: Jing, Wei, et al.
Publicado: (2020)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation
por: Serna-Blasco, Roberto, et al.
Publicado: (2022)

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
por: Zhang, Qiuyi, et al.
Publicado: (2016)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
por: Hong, Lingzhi, et al.
Publicado: (2022)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
por: Zhang, Ruiguang, et al.
Publicado: (2016)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Efficacy and safety of original EGFR-TKI combined with bevacizumab in advanced lung adenocarcinoma patients harboring EGFR-mutation experiencing gradual progression after EGFR-TKI treatment: a single-arm study
por: Long, Jianlin, et al.
Publicado: (2022)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
por: Lv, Yang, et al.
Publicado: (2016)

Mallory‐Weise syndrome in a patient treated with EGFR‐TKI
por: Okauchi, Shinichiro, et al.
Publicado: (2017)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
por: Kim, Seo Yun, et al.
Publicado: (2019)

EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
por: Gieszer, Balazs, et al.
Publicado: (2021)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

Osteosarcomatous Differentiation in Rebiopsy Specimens of Pulmonary Adenocarcinoma with EGFR-TKI Resistance
por: Ahn, Hyein, et al.
Publicado: (2018)

Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas
por: Lee, Ting-Fang, et al.
Publicado: (2018)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
por: Yang, Zhengyu, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
por: Goldberg, Michael E., et al.
Publicado: (2018)

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma
por: Hong, Xuan, et al.
Publicado: (2023)

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC
por: Incharoen, Pimpin, et al.
Publicado: (2019)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2021)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy
por: Yu, Xin, et al.
Publicado: (2021)

The correlation of p22(phox) and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma
por: Kobayashi, Masayuki, et al.
Publicado: (2019)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
por: Kang, Da Hyun, et al.
Publicado: (2020)

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
por: Chen, Hongjin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8a6a2qlicginnaodmam25r68km